Patents by Inventor Jennifer Iaci

Jennifer Iaci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF NEUREGULIN TO TREAT PERIPHERAL NERVE INJURY
    Publication number: 20230117985
    Abstract: The disclosure provides compositions and methods for preventing, ameliorating a sign or symptom of, or treating peripheral nerve injury.
    Type: Application
    Filed: March 28, 2022
    Publication date: April 20, 2023
    Inventors: Anthony O. Caggiano, Anthony J. Bella, Anindita Ganguly, Jennifer Iaci, Tom Parry, Raymond Warren Colburn
  • Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
    Patent number: 11235031
    Abstract: The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any potential side effects.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: February 1, 2022
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Anthony O. Caggiano, Anindita Ganguly, Jennifer Iaci, Tom Parry
  • COMPOSITIONS AND METHODS FOR TREATMENT DURING NON-ACUTE PERIODS FOLLOWING CNS NEUROLOGICAL INJURY
    Publication number: 20200368318
    Abstract: This invention relates to treatment of neuroinjury in a post-acute window or in a chronic period following neuroinjury.
    Type: Application
    Filed: April 29, 2020
    Publication date: November 26, 2020
    Inventors: Anthony Caggiano, Jennifer Iaci
  • THERAPEUTIC DOSING OF A NEUREGULIN OR A FRAGMENT THEREOF FOR TREATMENT OR PROPHYLAXIS OF HEART FAILURE
    Publication number: 20200338165
    Abstract: The invention relates to treatment and prevention of heart failure in a mammal. The invention provides a dosing regimen whereby the therapeutic benefits conferred by administration of peptide comprising an epidermal growth factor-like domain, e.g., a neuregulin such as glial growth factor 2 (GGF2) or a functional fragment thereof, are maintained and/or enhanced, while concomitantly minimizing any potential side effects.
    Type: Application
    Filed: July 15, 2020
    Publication date: October 29, 2020
    Inventors: Anthony O. Caggiano, Anindita Ganguly, Jennifer Iaci, Tom Parry
  • Compositions and methods for treatment during non-acute periods following CNS neurological injury
    Patent number: 10668131
    Abstract: This invention relates to treatment of neuroinjury in a post-acute window or in a chronic period following neuroinjury.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: June 2, 2020
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Anthony Caggiano, Jennifer Iaci
  • THERAPEUTIC DOSING OF A NEUREGULIN OR A SUBSEQUENCE THEREOF FOR TREATMENT OR PROPHYLAXIS OF HEART FAILURE
    Publication number: 20200009228
    Abstract: The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any potential side effects.
    Type: Application
    Filed: September 9, 2019
    Publication date: January 9, 2020
    Inventors: Anthony O. Caggiano, Anindita Ganguly, Jennifer Iaci, Tom Parry
  • Compositions and methods of using chondroitinase ABCI mutants
    Patent number: 10323240
    Abstract: One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: June 18, 2019
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Anthony O. Caggiano, Jennifer Iaci, Andrea Vecchione, Elizabeth Hunter
  • Therapeutic Dosing of a Neuregulin or a Fragment Thereof for Treatment or Prophylaxis of Heart Failure
    Publication number: 20180303904
    Abstract: The invention relates to treatment and prevention of heart failure in a mammal. The invention provides a dosing regimen whereby the therapeutic benefits conferred by administration of peptide comprising an epidermal growth factor-like domain, e.g., a neuregulin such as glial growth factor 2 (GGF2) or a functional fragment thereof, are maintained and/or enhanced, while concomitantly minimizing any potential side effects.
    Type: Application
    Filed: April 19, 2018
    Publication date: October 25, 2018
    Inventors: Anthony O. Caggiano, Anindita Ganguly, Jennifer Iaci, Tom Parry
  • Therapeutic Dosing of a Neuregulin or a Subsequence Thereof for Treatment or Prophylaxis of Heart Failure
    Publication number: 20180280477
    Abstract: The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any potential side effects.
    Type: Application
    Filed: March 29, 2018
    Publication date: October 4, 2018
    Inventors: Anthony O. Caggiano, Anindita Ganguly, Jennifer Iaci, Tom Parry
  • Compositions and methods of using chondroitinase ABCI mutants
    Patent number: 9987340
    Abstract: The present disclosure relates to protein and nucleic acid mutants of chondroitinase ABCI. Such nucleic acid mutants encode for chondroitinase ABCI mutant enzymes exhibiting altered chondroitin lyase activity or increased resistance to inactivation from stressors including UV light or heat. Methods of using such nucleic acid mutants encoding chondroitinase ABCI mutant enzymes is also provided.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: June 5, 2018
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Anthony O. Caggiano, Andrea Vecchione, Jennifer Iaci
  • Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
    Patent number: 9956266
    Abstract: The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any potential side effects.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: May 1, 2018
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Anthony O. Caggiano, Anindita Ganguly, Jennifer Iaci, Tom Parry
  • FUSION PROTEINS FOR THE TREATMENT OF CNS
    Publication number: 20180073007
    Abstract: This disclosure relates to compositions capable of use in the treatment of spinal cord injuries and related disorders of the central nervous system (CNS), and in particular, compositions including proteoglycan degrading molecules and compositions capable of blocking and/or over coming the activity of neuronal growth inhibitory molecules, as well as fusion proteins which includes a proteoglycan degrading domain and a domain capable of blocking and or over coming the activity of neuronal growth inhibitory molecules.
    Type: Application
    Filed: November 6, 2014
    Publication date: March 15, 2018
    Inventors: Elliott A. GRUSKIN, Anthony O. CAGGIANO, Gargi ROY, Jennifer IACI, Michael P. ZIMBER
  • COMPOSITIONS AND METHODS OF USING CHONDROITINASE ABCI MUTANTS
    Publication number: 20180066245
    Abstract: One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.
    Type: Application
    Filed: October 20, 2017
    Publication date: March 8, 2018
    Inventors: Anthony O. CAGGIANO, Jennifer IACI, Andrea VECCHIONE, Elizabeth HUNTER
  • Compositions and methods of using chondroitinase ABCI mutants
    Patent number: 9834764
    Abstract: One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: December 5, 2017
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Anthony O. Caggiano, Jennifer Iaci, Andrea Vecchione, Elizabeth Hunter
  • COMPOSITIONS AND METHODS FOR TREATMENT DURING NON-ACUTE PERIODS FOLLOWING CNS NEUROLOGICAL INJURY
    Publication number: 20170252406
    Abstract: This invention relates to treatment of neuroinjury in a post-acute window or in a chronic period following neuroinjury.
    Type: Application
    Filed: November 21, 2016
    Publication date: September 7, 2017
    Inventors: Anthony Caggiano, Jennifer Iaci
  • COMPOSITIONS AND METHODS OF USING CHONDROITINASE ABCI MUTANTS
    Publication number: 20170028038
    Abstract: The present disclosure relates to protein and nucleic acid mutants of chondroitinase ABCI. Such nucleic acid mutants encode for chondroitinase ABCI mutant enzymes exhibiting altered chondroitin lyase activity or increased resistance to inactivation from stressors including UV light or heat. Methods of using such nucleic acid mutants encoding chondroitinase ABCI mutant enzymes is also provided.
    Type: Application
    Filed: August 5, 2016
    Publication date: February 2, 2017
    Applicant: ACORDA THERAPEUTICS, INC.
    Inventors: Anthony O. CAGGIANO, Andrea VECCHIONE, Jennifer IACI
  • COMPOSITIONS AND METHODS OF USING CHONDROITINASE ABCI MUTANTS
    Publication number: 20170009222
    Abstract: One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.
    Type: Application
    Filed: July 21, 2016
    Publication date: January 12, 2017
    Applicant: Acorda Therapeutics, Inc.
    Inventors: Anthony O. CAGGIANO, Jennifer IACI, Andrea VECCHIONE, Elizabeth HUNTER
  • Use of Neuregulin to Treat Peripheral Nerve Injury
    Publication number: 20160346353
    Abstract: The disclosure provides compositions and methods for preventing, ameliorating a sign or symptom of, or treating peripheral nerve injury.
    Type: Application
    Filed: December 22, 2015
    Publication date: December 1, 2016
    Inventors: Anthony O. Caggiano, Anthony J. Bella, Anindita Ganguly, Jennifer Iaci, Tom Parry, Raymond Warren Colburn
  • Compositions and methods for treatment during non-acute periods following CNS neurological injury
    Patent number: 9498515
    Abstract: This invention relates to treatment of neuroinjury in a post-acute window or in a chronic period following neuroinjury.
    Type: Grant
    Filed: August 17, 2009
    Date of Patent: November 22, 2016
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Anthony Caggiano, Jennifer Iaci
  • Compositions and methods of using chondroitinase ABCI mutants
    Patent number: 9410141
    Abstract: The present disclosure relates to protein and nucleic acid mutants of chondroitinase ABCI. Such nucleic acid mutants encode for chondroitinase ABCI mutant enzymes exhibiting altered chondroitin lyase activity or increased resistance to inactivation from stressors including UV light or heat. Methods of using such nucleic acid mutants encoding chondroitinase ABCI mutant enzymes is also provided.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: August 9, 2016
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Anthony O. Caggiano, Andrea Vecchione, Jennifer Iaci